Junction: Oncology

MTC

Case Report: MTC Responds to Treatment With Pralsetinib

Metastatic medullary thyroid carcinoma (MTC) with somatic variants of unknown significance in the RET gene can respond to treatment with pralsetinib, according to a recently published case report in the European Thyroid Journal. The case involved a 48-year-old man with liver metastases that were identified during a cholecystectomy. Computer tomography and magnetic resonance imaging revealed a primary…

Capsules

Selpercatinib Induces Durable and Sustained Responses in Patients With MTC

Patients with medullary thyroid carcinoma (MTC) treated with selpercatinib continue to show very durable responses in the phase1/2 LIBRETTO-001 clinical trial, according to an update published in the Annals of Oncology. This is the case whether or not they have received previous treatment with cabozantinib and vandetanib. These findings, which are based on additional patients…

systemic mastocytosis therapies

Durvalumab Appears to Improve Survival in CCA

Results from the TOPAZ-1 phase 3 clinical trial suggest that durvalumab (Imfinzi®) combined with chemotherapy could increase overall survival in patients with biliary tract malignancies, including cholangiocarcinoma (CCA), according to a recently published press release. The trial results indicated that the combination of durvalumab and gemcitabine plus cisplatin can increase overall survival in patients with biliary…

Photodynamic therapy research in lab

Photodynamic Therapy Linked With Increased Survival in Cholangiocarcinoma

Percutaneous transhepatic cholangioscopy (PTCS)-guided photodynamic therapy (PDT) appears to increase survival and improve overall quality of life in patients with postoperative cholangiocarcinoma (CCA) recurrence, according to an article recently published in Photodiagnosis and Photodynamic Therapy. Although surgical resection is the preferred treatment for CCA, the majority of patients have advanced disease at the time of diagnosis…

Doctor viewing MRI brain scans

MEGNA Scoring System Insufficient in Assessing Survival in CCA

Tumor multifocality, extension, grade, lymph node involvement, and age (MEGNA), a prognostic scoring system, may not be enough to assess overall survival and disease-free survival in patients with cholangiocarcinoma (CCA), according to a retrospective study. The findings showed that the MEGNA score (c‐index=0.60) was similar to the frequently used tumor burden score (TBS; c‐index=0.58) and…

Immunotherapy

Dual-Agent Immunotherapy May Effectively Treat Refractory Cholangiocarcinoma

Sequential immunotherapy may be beneficial for patients with cholangiocarcinoma (CCA), although its indications are still unclear, according to a case series study recently published in the American Journal of Clinical Oncology. “This study can also serve as the foundation to build further tests on the true effectiveness and ideal duration of sequential therapy with dual immunotherapy…

choriocarcinoma biopsy under microscopy

Laparoscopic ILSeg8 May Effectively Treat Malignant Tumors in CCA

Laparoscopic isolated liver segmentectomy 8 (ILSeg8) using the extrahepatic Glissonian approach and hepatic vein root at first parenchymal dissection may be feasible, safe, and oncologically acceptable for patients with intrahepatic cholangiocarcinoma (CCA), hepatocellular carcinoma, and metastatic liver tumors, according to a propensity score–matched study. The results showed that patients who underwent laparoscopic ILSeg8 had significantly…

Medullary Thyroid Cancer Diagnosis

Radiolabeled Somatostatin Analogs May Be Useful in Managing Recurrent MTC

Radiolabeled somatostatin analogs can be useful for the management of recurrent medullary thyroid carcinoma (MTC) after a thyroidectomy, according to a study. The results showed that gallium-68 dodecane tetraacetic acid tyr3-octreotate positron emission tomography-computed tomography (68Ga-DOTATAE PET-CT) had a relatively high detection rate, and peptide receptor radionuclide therapy with 177Lu-DOTATATE was a safe alternative for…

CT scan

New Study to Investigate 18F-PSMA Positron Emission Tomography for MTC

A new observational study aims to assess the feasibility of using F-18 labeled prostate-specific membrane antigen (18F-PSMA) as a tracer for positron emission tomography/computer tomography (PET/CT) imaging for the staging of medullary thyroid carcinoma (MTC). The study will also compare 18F-PSMA to the most commonly used tracer in clinical practice, F-18 labeled fluorodeoxyglucose (18F-FDG), to…

Next post in MTC News Briefs